Susan Halabi

Biostatistician Susan Halabi, PhD, presented at ASCO the results of her PCF-funded study that may ultimately help speed treatments to patients.

Here are some of the DCI faculty, researchers and nurses whose work has recently been featured by the media, academic trade publications & journals.

Enrolling a large number of Black men, Duke researchers found potential new paths for improved studies and treatments.

Here are some of the DCI faculty, researchers and nurses whose work has recently been featured by the media, academic trade publications & journals.

Various genetic alterations in circulating tumor cells were associated with clinical outcomes and resistance to hormone therapy in patients with mCRPC.

A research team led by Andrew Armstrong, MD, MSc, identifies new targets for treating non-clear cell renal carcinoma.

Here are some of the DCI faculty, researchers and nurses whose work has recently been featured by the media, academic trade publications & journals.

Susan Halabi, PhD, is co-leading a project to create a large international registry of data from prostate cancer patients treated with various PARP inhibitors.

Here are some of the DCI faculty, researchers and nurses whose work has recently been featured by the media, academic trade publications & journals.

Here are some of the DCI physicians, physician-scientists, researchers & nurses whose work has recently been featured by the media, academic trade publications & journals.

Duke Cancer Institute will present more than 100 abstracts across multiple cancer types during the ASCO20 Virtual Scientific Program of the 2020 ASCO Annual Meeting.

Duke Cancer Institute member and family physician Kevin Oeffinger, MD, has been named a Fellow of the American Society of Clinical Oncology (FASCO). 

Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.

Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.

Black men are underrepresented in clinical trials for prostate cancer, despite an almost two-fold greater incidence and mortality of disease in black versus white populations.